Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study

Objective:. Residual cardiovascular risk in patients with coronary heart disease (CHD) still needs to be addressed in real-world practice. This study aimed to examine the clinical effectiveness of nicorandil and nitrate in addition to optimal treatment for CHD patients. Methods:. This retrospective...

Full description

Saved in:
Bibliographic Details
Main Authors: Ping Li, Juan Chen, Na Li, Xiang You, Lan Shen, Ning Zhou
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2023-09-01
Series:Cardiology Discovery
Online Access:http://journals.lww.com/10.1097/CD9.0000000000000092
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849701475729539072
author Ping Li
Juan Chen
Na Li
Xiang You
Lan Shen
Ning Zhou
author_facet Ping Li
Juan Chen
Na Li
Xiang You
Lan Shen
Ning Zhou
author_sort Ping Li
collection DOAJ
description Objective:. Residual cardiovascular risk in patients with coronary heart disease (CHD) still needs to be addressed in real-world practice. This study aimed to examine the clinical effectiveness of nicorandil and nitrate in addition to optimal treatment for CHD patients. Methods:. This retrospective cohort study included patients with CHD between October 2009 and March 2020 from 2 tertiary hospitals in Wuhan, China. Patients were grouped into nicorandil and nitrate groups depending on the first recorded antianginal therapy. Demographic and clinical data were collected from databases of the 2 hospitals. The primary outcome was cumulative 18-month major adverse cardiovascular event (MACE)-free survival, which was evaluated by Kaplan-Meier analysis. Propensity score matching (PSM) and multivariate Cox regression were adopted to adjust for confounding factors. Results:. A total of 14,275 patients were analyzed, including 590 and 13,685 patients in the nicorandil and nitrate groups, respectively. With a median follow-up of 0.88 (Q1, Q3: 0.21, 1.54) years, the cumulative 18-month MACE-free survival rates were comparable between the 2 groups (80.0% vs. 75.0%, adjusted hazard ratio (aHR): 1.04, 95% confidence interval (CI): 0.42–2.56, P = 0.982,7) after 1:4 PSM. The cumulative 18-month stroke-free survival rate was significantly higher in the nicorandil group compared to the nitrate group (93.0% vs. 84.0%, aHR: 0.56, 95% CI: 0.34–0.92, P = 0.023,5). Conclusion:. This retrospective study showed that nicorandil and nitrate have similar 18-month rates of MACEs in CHD patients, but nicorandil is associated with lower incidence of stroke compared to nitrate. More studies need to be conducted to validate this association and explore the long-term benefit of nicorandil use on the occurrence of MACEs in the future.
format Article
id doaj-art-db88191c05e1403e94f97cf9c33a15bd
institution DOAJ
issn 2096-952X
2693-8499
language English
publishDate 2023-09-01
publisher Wolters Kluwer Health/LWW
record_format Article
series Cardiology Discovery
spelling doaj-art-db88191c05e1403e94f97cf9c33a15bd2025-08-20T03:17:55ZengWolters Kluwer Health/LWWCardiology Discovery2096-952X2693-84992023-09-013315215810.1097/CD9.0000000000000092202309000-00002Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort StudyPing Li0Juan Chen1Na Li2Xiang You3Lan Shen4Ning Zhou51 Department of Cardiothoracic Surgery, Union Hospital of Huazhong University of Science and Technology, Wuhan, Hubei 430022, China2 Department of Cardiology, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, Hubei 430014, China3 Division of Cardiology, Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei 430030, China4 Chugai Pharma China Co., Ltd., Shanghai 200020, China5 Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200025, China.3 Division of Cardiology, Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei 430030, ChinaObjective:. Residual cardiovascular risk in patients with coronary heart disease (CHD) still needs to be addressed in real-world practice. This study aimed to examine the clinical effectiveness of nicorandil and nitrate in addition to optimal treatment for CHD patients. Methods:. This retrospective cohort study included patients with CHD between October 2009 and March 2020 from 2 tertiary hospitals in Wuhan, China. Patients were grouped into nicorandil and nitrate groups depending on the first recorded antianginal therapy. Demographic and clinical data were collected from databases of the 2 hospitals. The primary outcome was cumulative 18-month major adverse cardiovascular event (MACE)-free survival, which was evaluated by Kaplan-Meier analysis. Propensity score matching (PSM) and multivariate Cox regression were adopted to adjust for confounding factors. Results:. A total of 14,275 patients were analyzed, including 590 and 13,685 patients in the nicorandil and nitrate groups, respectively. With a median follow-up of 0.88 (Q1, Q3: 0.21, 1.54) years, the cumulative 18-month MACE-free survival rates were comparable between the 2 groups (80.0% vs. 75.0%, adjusted hazard ratio (aHR): 1.04, 95% confidence interval (CI): 0.42–2.56, P = 0.982,7) after 1:4 PSM. The cumulative 18-month stroke-free survival rate was significantly higher in the nicorandil group compared to the nitrate group (93.0% vs. 84.0%, aHR: 0.56, 95% CI: 0.34–0.92, P = 0.023,5). Conclusion:. This retrospective study showed that nicorandil and nitrate have similar 18-month rates of MACEs in CHD patients, but nicorandil is associated with lower incidence of stroke compared to nitrate. More studies need to be conducted to validate this association and explore the long-term benefit of nicorandil use on the occurrence of MACEs in the future.http://journals.lww.com/10.1097/CD9.0000000000000092
spellingShingle Ping Li
Juan Chen
Na Li
Xiang You
Lan Shen
Ning Zhou
Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study
Cardiology Discovery
title Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study
title_full Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study
title_fullStr Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study
title_full_unstemmed Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study
title_short Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study
title_sort real world major adverse cardiovascular events of nicorandil and nitrate in coronary heart disease in central china a retrospective cohort study
url http://journals.lww.com/10.1097/CD9.0000000000000092
work_keys_str_mv AT pingli realworldmajoradversecardiovasculareventsofnicorandilandnitrateincoronaryheartdiseaseincentralchinaaretrospectivecohortstudy
AT juanchen realworldmajoradversecardiovasculareventsofnicorandilandnitrateincoronaryheartdiseaseincentralchinaaretrospectivecohortstudy
AT nali realworldmajoradversecardiovasculareventsofnicorandilandnitrateincoronaryheartdiseaseincentralchinaaretrospectivecohortstudy
AT xiangyou realworldmajoradversecardiovasculareventsofnicorandilandnitrateincoronaryheartdiseaseincentralchinaaretrospectivecohortstudy
AT lanshen realworldmajoradversecardiovasculareventsofnicorandilandnitrateincoronaryheartdiseaseincentralchinaaretrospectivecohortstudy
AT ningzhou realworldmajoradversecardiovasculareventsofnicorandilandnitrateincoronaryheartdiseaseincentralchinaaretrospectivecohortstudy